Acetylsalicylic Acid, Cardiovascular Diseases and Nanotechnology - Abstract
Acetylsalicylic acid (ASA) is the most widespread antiplatelet agent used now a day due to its efficacy and low cost. However, several side-effects are well-known to limit ASA usage. This review covers the recommended guidelines for ASA usage for primary and secondary prevention in cardiovascular diseases, showing when this treatment is recommended, the concomitant usage of proton pump inhibitors in ASA therapy and if enteric-coated ASA is well established. Furthermore, we show promising studies and future perspectives on the exploration of different administration routes as well as the usage of nanotechnology to lower therapy-related side-effects, particularly gastrointestinal bleeding and ASA resistance.